Cytel

Recent Posts

Publication Reveals New Promise for Promising Zone Designs

Posted by Cytel

Feb 8, 2019 5:35:00 AM

 

A 2018 publication in the  Biometrical Journal by Cytel’s Cyrus Mehta, Lingyun Liu and Sam Hsiao, ‘Optimal Promising Zone Designs’ (1) marks a new milestone for adaptive sample size re-estimation. Inspired by insights from the team's work with a number of Cytel's strategic consulting clients, it presents an easy to implement and new iteration of the popular promising zone design. The basic...

Read More

Topics: adaptive sample size re-estimation, Promising Zone, adaptive trials


Career Perspectives: Interview with Tina Checchio, Associate Director, Quantitative Pharmacology & Pharmacometrics

Posted by Cytel

Jan 30, 2019 6:30:00 AM

QPP remains at the heart of model based drug development. Short for Quantitative Pharmacology & Pharmacometrics, it refers to several types of quantitative modeling including meta-analysis, PK/PD, statistical modeling and the modeling of go-no-go decision rules. Cytel’s expert Quantitative Pharmacology and Pharmacometrics group delivers high quality solutions to help our customers get those...

Read More

Topics: Clinical Research Services, Statistical Analysis, careers, clinical data management, clinical research, Data Management, Statistical Programming, quantitative decision-making, model-informed-drug-development, Early Phase Trials, Phase I, pharmacometrics, pharmacology


Podcast: Overcoming Phase 1 Development Challenges

Posted by Cytel

Jan 10, 2019 8:00:00 AM

 

Nand Kishore Rawat is a Director and Head, Early Phase Biostatistics based in the King of Prussia, PA Cytel office. We recently spoke with Nand for the Cytel podcast to gain his thoughts on the unique aspects of Phase 1 development and where innovative approaches supported by thorough planning can meet these challenges head-on.  Read on for key insights or listen to the podcast. 

Read More

Topics: clinical research, clinical trials, biostatistics, Cytel Strategic Consulting, clinical development, Phase I, pharmacometrics, quantitative decision-making


New Year Round-Up: Your Favorite Posts of 2018

Posted by Cytel

Jan 8, 2019 6:47:00 AM

Happy New Year! As we look ahead to future successes and the new advancements in drug development that 2019 will bring, we are taking a moment to reflect on the topics that resonated most with our community on the Cytel blog in 2018. While these 6 most popular blogs encompass a variety of topics from across the data science, statistics, and statistical programming space, they all have in...

Read More

Topics: clinical research, clinical trials, adaptive trials, feature selection, Clinical Data, CDISC, meta-analysis, data science


Highlights from the PhUSE EU Connect

Posted by Cytel

Dec 11, 2018 6:36:00 AM

PhUSE EU Connect 2018 took place in Germany’s financial capital Frankfurt, 4th - 7th November and brought together a range of experts to tackle the most pressing issues facing statistical programmers today. The agenda was superb with 143 presentations in 16 different streams and nearly 30 posters. This year’s event theme ‘Future Forward’ did not disappoint and there were some very...

Read More

Topics: adaptive designs, data science, careers, R programming, Statistical Programming, PhUSE, SDTM, machine learning, CDISC, FDA


Can Statisticians Contribute to Enhance the Position of Patients in Clinical Trials?

Posted by Cytel

Nov 12, 2018 8:04:00 AM

 

In this blog, we talk with Robert Greene, Founder and President of the HungerNDThirst Foundation, about his upcoming presentation at Cytel’s East User Group Meeting on 14th and 15th November at Merck in Darmstadt, Germany. Robert will bring a fresh perspective to the discussion of the role statisticians can play in enhancing the position of patients in clinical trials. Patient-centricity is a...

Read More

Topics: Adaptive Clinical Trials, Trial Design, phase 2, Program and Portfolio Optimization, Simulations, East, adaptive designs, Bayesian Methods, Phase I, biostatistics, Statistical Innovations in Clinical Development, randomization, patientricity


Webinar: Basket Trial Design and Implementation Considerations

Posted by Cytel

Nov 9, 2018 11:33:00 AM

We are excited to announce an upcoming webinar in our Trial Innovations Series. “Basket Trials: Design and Implementation Considerations” on 4th December 2018 at 11am EST. Noted basket trial expert, Robert (Bob) Beckman will share his most recent experiences with Cytel Strategic Consulting Statistician Sam Hsiao on expanding the application of this innovative breed of trials. Bob acts as a...

Read More

Topics: Oncology, basket trials, webinar


Data Management Fundamentals for Your Next Clinical Trial

Posted by Cytel

Nov 8, 2018 9:55:00 AM

 

 Data is the most crucial asset in any clinical trial and is used to ultimately drive the decision-making process related to the development candidate. Therefore, for any sponsor, paying close attention to the data management aspects of clinical operations should be paramount. The principles of data management are simple and well-founded. However, the application of these principles needs...

Read More

Topics: Data Management


New publication addresses critical issues in ultra-orphan indications

Posted by Cytel

Nov 5, 2018 7:01:00 AM

Cytel biostatisticians Cyrus Mehta and Lingyun Liu, together with Charles Theuer, CEO of TRACON Pharmaceuticals have recently co-authored a publication in the journal Annals of Oncology: “ An Adaptive Population Enrichment Phase 3 Trial of TRC105 and Pazopanib Versus Pazopanib Alone in Patients with Advanced Angiosarcoma (TAPPAS Trial)”. The paper explores the features of this innovative...

Read More

Topics: clinical research, clinical trials, Oncology, Precision Medicine, adaptive trials, adaptive designs, adaptive sample size re-estimation, population enrichment


Incorporating patient preferences and values into risk-benefit calculations opens new horizons

Posted by Cytel

Oct 26, 2018 8:59:00 AM

 

Read More

Topics: clinical research, clinical trials, clinical development, biostatistics, patientricity


Career Perspectives: Interview with Munshi Imran Hossain, Senior Data Scientist

Posted by Cytel

Oct 23, 2018 11:00:00 AM

Cytel data scientists apply advanced statistical techniques including predictive modeling of biological processes and drug interactions to unlock the potential of big data.

In this blog we talk to Munshi Imran, who is based in Pune, India to find out more about his career path, current role at Cytel and his interests outside of work.

Read More

Topics: Statistical Analysis, careers, clinical research, Statistical Programming, CRO, Recruitment, Cytel Strategic Consulting, adaptive designs, Adaptive Clinical Trials, clinical trials, Regulation, big data, Trial Design Software, Software Simulations, genetic algorithm


Selection Bias for Treatments with Positive Phase 2 Results with Simon Kirby

Posted by Cytel

Oct 18, 2018 11:09:00 AM

 

In this blog, we talk with Simon Kirby, former Senior Director at Pfizer, about his upcoming presentation at Cytel’s East User Group Meeting on 14th and 15th November at Merck Darmstadt, in Germany. Simon will address the topic of Selection Bias for Treatments with Positive Phase 2 Results and in this blog he explains why this is a key topic of particular relevance for pharmaceutical companies...

Read More

Topics: Adaptive Clinical Trials, Trial Design, phase 2, Program and Portfolio Optimization, Simulations, East, adaptive designs, Bayesian Methods, Phase I, go-no-go, biostatistics, Statistical Innovations in Clinical Development, randomization


Highlights from the SCDM 2018 Conference

Posted by Cytel

Oct 16, 2018 11:00:00 AM

The Society for Clinical Data Management (SCDM) conference brought clinical data managers from around the world to Seattle-Bellevue, WA on September 23-26. The conference offered an unmatched opportunity to discover innovative solutions in the clinical data management industry. In this blog, we will share our data management colleagues' experiences, observed trends and contributions to the...

Read More

Topics: clinical data management, data manager, Clinical Data, clinical research, clinical trials, clinical development, CDM


When Knowledge Drives Results: The Impact of a Winning Data Strategy

Posted by Cytel

Oct 10, 2018 12:31:00 PM

Read More

Topics: CDISC, SDTM, Data Management, clinical data management


Interview with Stephen Senn: 70 Years and Still Here: The Randomized Clinical Trial and its Critics

Posted by Cytel

Oct 5, 2018 7:00:00 AM

 

We are delighted that Stephen Senn will be joining us at the EUGM on November 14th and 15th in Darmstadt, Germany. In this blog, we sit down for a discussion with Stephen about his career in statistics, his advice for early career statisticians, his upcoming research, and the topic of his presentation at the East User Group Meeting “70 Years Old and Still Here: the Randomized Clinical Trial...

Read More

Topics: Adaptive Clinical Trials, Trial Design, phase 2, Program and Portfolio Optimization, Simulations, East, adaptive designs, Bayesian Methods, Phase I, go-no-go, biostatistics, Statistical Innovations in Clinical Development, randomization


Decision Making in Development Programs with Targeted Therapies: with Heiko Götte

Posted by Cytel

Sep 27, 2018 9:00:00 AM

 

In this blog, we talk with Heiko Götte, Senior Expert Biostatistician at Merck about his upcoming presentation at Cytel’s East User Group Meeting on 14th and 15th November at Merck Darmstadt, in Germany. The topic Heiko will address is Decision Making in Development Programs with Targeted Therapies and he explains to us why this is a key topic for pharmaceutical companies today as they...

Read More

Topics: Adaptive Clinical Trials, Trial Design, phase 2, Program and Portfolio Optimization, Simulations, East, adaptive designs, Bayesian Methods, Phase I, Biomarkers, go-no-go


Career Perspectives: Interview with Adam Hamm, Director of Biostatistics

Posted by Cytel

Sep 20, 2018 1:04:00 PM

At Cytel we believe that expert statistical input has the power to shape the future of clinical development: de-risking portfolios, accelerating timelines, and increasing the probability of success.

In this blog we talk to Adam who lives in North Carolina United States to find out more about his career path, achievements, current role at Cytel and his interests outside of work.

Read More

Topics: Statistical Analysis, careers, clinical research, Statistical Programming, CRO, Recruitment, Cytel Strategic Consulting, biostatistics, adaptive designs, Adaptive Clinical Trials, clinical trials, Regulation


Could data science be about to revolutionize the regulatory approval of new drugs?

Posted by Cytel

Sep 10, 2018 6:52:00 AM

 

The biopharmaceutical and healthcare industries now collect more data than ever before due to advances in the variety of information sources combined with the ability to store vast quantities of diverse data. Sophisticated machine learning (ML) and artificial intelligence (AI) techniques allow us to accessand analyze any combination of a multitude of data sources. The way that traditional...

Read More

Topics: biostatistics, data science, real world evidence


Opportunities of FDA’s Complex Innovative Trial Design Pilot Meeting Program

Posted by Cytel

Sep 7, 2018 9:55:00 AM

 

On August 29th 2018, the FDA announced (1) that it would be establishing a Complex Innovative Trial Design (CID) Pilot Meeting Program. This follows the release earlier in August of a draft guidance (2) to help advance effective and innovative clinical trial designs early in drug development that can expedite new cancer therapies.

Read More

Topics: biostatistics, adaptive trials, adaptive sample size re-estimation, Seamless designs, FDA, Oncology


Podcast: Enhancing Patient Enrollment Forecasting with EnForeSys 2.0

Posted by Cytel

Sep 5, 2018 8:50:00 AM

 

EnForeSys is Cytel’s tool for patient recruitment planning. We have discussed on the blog recently with Tufts University's Center for the Study of Drug Development, Ken Getz, the problem the industry continues to face with patient recruitment, and the fact that most trials significantly exceed their original planned duration. In the face of this problem there's a pressing need to create more...

Read More

Topics: patient enrollment, enforesys, clinical trials


The Cytel blog keeps you up to speed with the latest developments in biostatistics and clinical biometrics.  Sign up for updates direct to your inbox. You can unsubscribe at any time.

 

Posts by Topic

see all

Recent Posts